Interestingly, aberrations in circulating species of the sphingolipid pathways have been consistently found in patients with localized PCa that clinically progressed or with metastatic/castration therapy resistant PCa [7–9], in PCa resistant to docetaxel [10] or to androgen receptor signalling inhibitors [11], as well as in neuroendocrine PCa [12] and in prostate cells treated with fatty acid synthase inhibitor, highlighting a role also in mediation of lipid damage [13]. This evidence concerns the gene FASN and posterior cortical atrophy.